Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1 091,51
-2,30
-0,21%
—1 093,811 096,521 100,221 091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1 237,98
-16,83
-1,34%
—1 254,811 253,011 253,871 226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1 744,71
-16,40
-0,93%
—1 761,111 764,271 766,881 744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3 260,69
+48,86
+1,52%
—3 211,833 227,213 268,383 226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1 466,80
-7,72
-0,52%
—1 474,521 479,031 481,041 466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2 397,50
+5,38
+0,22%
—2 392,122 396,952 421,222 382,32——
NTLA:NASDAQ
Intellia Therapeutics Inc
13,26 USD
-1,63%
(-0,22) 1D
13,24 USD
-0,15% (-0,020)
After hours
Closed: 1-май, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NTLA...
Open
13,39 USD
High
13,54 USD
Low
12,80 USD
Mkt. cap
1,76 млд
Avg. vol.
3,15 млн
Volume
5,80 млн
52-wk high
28,25 USD
52-wk low
6,83 USD
EPS
-3,81 USD
Beta
1,99
Shares outstanding
118,13 млн
No. of employees
377
News stories
From sources across the web
Profile
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
About Intellia Therapeutics Inc
CEOJohn Leonard
Employees377
Founded2014
HeadquartersКембридж, Массачусетс, Америка Кошмо Штаттары
Sector-
Websiteintelliatx.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025-ж. мар.
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
Revenue
16,63 млн
14,24 млн
13,78 млн
23,02 млн
Cost of goods sold
108,43 млн
80,53 млн
78,95 млн
73,63 млн
Cost of revenue
108,43 млн
80,53 млн
78,95 млн
73,63 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
29,01 млн
43,71 млн
46,31 млн
48,10 млн
Operating expense
29,01 млн
43,71 млн
46,31 млн
48,10 млн
Total operating expenses
137,43 млн
124,24 млн
125,26 млн
121,73 млн
Operating income
-120,81 млн
-110,00 млн
-111,48 млн
-98,71 млн
Other non operating income
-
-
-
-
EBT including unusual items
-114,33 млн
-101,26 млн
-101,32 млн
-95,79 млн
EBT excluding unusual items
-112,20 млн
-102,59 млн
-104,76 млн
-92,23 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-114,33 млн
-101,26 млн
-101,32 млн
-95,79 млн
Net profit margin
-687,61%
-710,81%
-735,19%
-416,15%
Earnings per share
-1,10
-0,98
-0,92
-0,83
Interest and investment income
8,60 млн
7,40 млн
6,71 млн
6,48 млн
Interest expense
-
-
-
-
Net interest expenses
8,60 млн
7,40 млн
6,71 млн
6,48 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-118,31 млн
-107,52 млн
-109,06 млн
-96,33 млн
Gain or loss from assets sale
-
-
-
527,00 миң
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer